Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Virios Therapeutics (VIRI)
NASDAQ:VIRI
Holding VIRI?
Track your performance easily
VIRI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.16 - $2.24
Previous Close$0.25
Volume1.22M
Average Volume (3M)1.24M
Market Cap
$6.94M
Enterprise Value$3.62M
Total Cash (Recent Filing)$3.32M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.81
Next Earnings
Aug 08, 2024EPS Estimate
-$0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding19,257,937
10 Day Avg. Volume1,074,551
30 Day Avg. Volume1,242,603
Standard Deviation0.38
R-Squared0.04
Alpha-0.00844
Financial Highlights & Ratios
Price to Book (P/B)1.37
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.67
Forecast
1Y Price Target
$0.70Price Target Upside186.77% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Virios Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsIMC-2 was successful in a P2a study in Long COVID, demonstrating statistically significant improvements in fatigue and orthostatic intolerance and other measures.
Financial StabilityVirios has a very low cash burn rate and the $2.4M raised at the end of 1Q24 along with the approximately $1.6M raised in May should provide financial runway into 1Q25.
Product DevelopmentVirios is developing IMC-2, a combination of the antiviral valacyclovir and the NSAID celecoxib, and IMC-1, a combination of famciclovir and celecoxib, for Long COVID and fibromyalgia, respectively.
Bears Say
Financial PerformanceThe company reported no revenues in the quarter and a net loss of $0.07 per share, worse than the consensus estimated net loss of $0.04 per share.
Resource ConstraintsThe company may not have the resources to independently conduct a large late-stage study to support approval and may need to seek a partner to co-develop IMC-2.
Stock PerformanceThe miss in the P2b FM study drove VIRI shares to an all-time low and they have not yet recovered.
---
Ownership Overview
3.02% Insiders
1.79% Mutual Funds
0.98% Other Institutional Investors
94.21% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VIRI FAQ
What was Virios Therapeutics’s price range in the past 12 months?
Virios Therapeutics lowest stock price was $0.15 and its highest was $2.24 in the past 12 months.
What is Virios Therapeutics’s market cap?
Currently, no data Available
When is Virios Therapeutics’s upcoming earnings report date?
Virios Therapeutics’s upcoming earnings report date is Aug 08, 2024 which is 16 days ago.
How were Virios Therapeutics’s earnings last quarter?
Virios Therapeutics released its earnings results on May 09, 2024. The company reported -$0.07 earnings per share for the quarter, missing the consensus estimate of -$0.04 by -$0.03.
Is Virios Therapeutics overvalued?
According to Wall Street analysts Virios Therapeutics’s price is currently Undervalued.
Does Virios Therapeutics pay dividends?
Virios Therapeutics does not currently pay dividends.
What is Virios Therapeutics’s EPS estimate?
Virios Therapeutics’s EPS estimate is -$0.06.
How many shares outstanding does Virios Therapeutics have?
Virios Therapeutics has 27,757,936 shares outstanding.
What happened to Virios Therapeutics’s price movement after its last earnings report?
Virios Therapeutics reported an EPS of -$0.07 in its last earnings report, missing expectations of -$0.04. Following the earnings report the stock price went down -13.953%.
Which hedge fund is a major shareholder of Virios Therapeutics?
Currently, no hedge funds are holding shares in VIRI
---
Virios Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-86.91%
12-Months-Change
Fundamentals
Return on Equity
-117.56%
Trailing 12-Months
Asset Growth
-50.55%
Trailing 12-Months
Company Description
Virios Therapeutics
Virios Therapeutics Inc is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia.
---
VIRI Earnings Call
Q1 2024
0:00 / 0:00
---
VIRI Stock 12 Month Forecast
Average Price Target
$0.70
▲(186.77% Upside)
Technical Analysis
Best Analysts Covering VIRI
1 Year
1 Year Success Rate
0/1 ratings generated profit
1 Year Average Return
-3.80%
initiated a buy rating 2 months ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -3.80% per trade.
---